Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $10000.0.

  • Inhibrx Biosciences' Capital Expenditures fell 9595.14% to $10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $47000.0, marking a year-over-year decrease of 9921.97%. This contributed to the annual value of $2.6 million for FY2024, which is 4345.74% down from last year.
  • Latest data reveals that Inhibrx Biosciences reported Capital Expenditures of $10000.0 as of Q3 2025, which was down 9595.14% from $21000.0 recorded in Q1 2025.
  • Inhibrx Biosciences' 5-year Capital Expenditures high stood at $3.4 million for Q4 2023, and its period low was $10000.0 during Q3 2025.
  • For the 3-year period, Inhibrx Biosciences' Capital Expenditures averaged around $829875.0, with its median value being $408000.0 (2023).
  • Examining YoY changes over the last 5 years, Inhibrx Biosciences' Capital Expenditures showed a top increase of 5659.05% in 2024 and a maximum decrease of 9953.52% in 2024.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Capital Expenditures stood at $3.4 million in 2023, then crashed by 99.54% to $16000.0 in 2024, then plummeted by 37.5% to $10000.0 in 2025.
  • Its last three reported values are $10000.0 in Q3 2025, $21000.0 for Q1 2025, and $16000.0 during Q4 2024.